Galmed Pharmaceuticals (GLMD) Total Current Liabilities (2013 - 2026)
Galmed Pharmaceuticals (GLMD) posted quarterly Total Current Liabilities of $2.1 million for Q1 2026, up 15.05% year-over-year from $1.8 million in Q1 2025, and down 26.92% quarter-over-quarter from $2.8 million in Q4 2025.
Galmed Pharmaceuticals (GLMD) Total Current Liabilities (2013 - 2026) Analysis & Trends
Galmed Pharmaceuticals' Total Current Liabilities history runs 14 years deep, the most recent figure standing at $2.1 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 15.05% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $2.1 million (up 15.05% YoY), while the FY2025 annual figure was $2.8 million, down 34.22% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $2.1 million, down from $2.8 million in the prior quarter.
- The five-year high for Total Current Liabilities was $5.6 million in Q1 2022, with the low at $184000.0 in Q1 2023.
- The 5-year median for Total Current Liabilities is $2.5 million (2024), against an average of $2.7 million.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities tumbled 96.74% in 2023, then soared 859.24% in 2024.
- Galmed Pharmaceuticals' Total Current Liabilities stood at $3.1 million in 2022, then retreated by 11.12% to $2.8 million in 2023, then soared by 57.27% to $4.3 million in 2024, then tumbled by 34.22% to $2.8 million in 2025, then dropped by 26.92% to $2.1 million in 2026.
- Business Quant data shows GLMD's Total Current Liabilities at $2.1 million in Q1 2026, $2.8 million in Q4 2025, and $2.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 630.93 Mn |
| 10 | Galmed Pharmaceuticals | 2.32 Mn | -9.56 Mn | - | 2.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.08 Mn |
| Dec 31, 2025 | 2.85 Mn |
| Sep 30, 2025 | 2.47 Mn |
| Jun 30, 2025 | 2.42 Mn |
| Mar 31, 2025 | 1.81 Mn |
| Dec 31, 2024 | 4.33 Mn |
| Sep 30, 2024 | 2.51 Mn |
| Jun 30, 2024 | 1.55 Mn |
| Mar 31, 2024 | 1.77 Mn |
| Dec 31, 2023 | 2.75 Mn |
| Sep 30, 2023 | 2.09 Mn |
| Jun 30, 2023 | 2.72 Mn |
| Mar 31, 2023 | 184,000.00 |
| Dec 31, 2022 | 3.09 Mn |
| Sep 30, 2022 | 5.03 Mn |
| Jun 30, 2022 | 2.73 Mn |
| Mar 31, 2022 | 5.65 Mn |
| Dec 31, 2021 | 5.88 Mn |
| Sep 30, 2021 | 6.35 Mn |
| Jun 30, 2021 | 7.01 Mn |